Antibe Therapeutics (TSE:ATE) Stock Price Up 13.5%

Shares of Antibe Therapeutics Inc. (TSE:ATEGet Free Report) shot up 13.5% during trading on Monday . The company traded as high as C$0.35 and last traded at C$0.30. 167,042 shares traded hands during trading, an increase of 23% from the average session volume of 135,475 shares. The stock had previously closed at C$0.26.

Antibe Therapeutics Stock Up 13.5 %

The firm’s fifty day simple moving average is C$0.30 and its two-hundred day simple moving average is C$0.58. The company has a market capitalization of C$15.64 million, a price-to-earnings ratio of -0.84 and a beta of 0.19. The company has a current ratio of 10.06, a quick ratio of 9.58 and a debt-to-equity ratio of 0.29.

Antibe Therapeutics Company Profile

(Get Free Report)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).

Read More

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.